文献速递免疫规划卫生政策与健康促进

COVID-19疫苗接种后急性播散性脑脊髓炎与横贯性脊髓炎的自身对照病例系列分析

Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
PubMed 文献 · Vaccine · 2024-02-12

结果显示ChAdOx1腺病毒载体疫苗与ADEM(所有剂次RI 3.74,95%CI 1.02-13.70)和TM(第1剂RI 2.49,95%CI 1.07-5.79)存在关联,而mRNA疫苗未观察到关联。绝对风险极低,ADEM为每百万剂0.78例,TM为每百万剂1.82例。

要点

  • ChAdOx1腺病毒载体COVID-19疫苗与ADEM(所有剂次RI 3.74,95%CI 1.02-13.70)和TM(第1剂RI 2.49,95%CI 1.07-5.79)住院存在关联。
  • mRNA COVID-19疫苗与ADEM或TM未观察到关联。
  • 接种后ADEM绝对风险为每百万剂0.78例,TM为每百万剂1.82例,潜在风险应与疫苗保护获益权衡。

核心结论

  • ChAdOx1腺病毒载体COVID-19疫苗接种与ADEM和TM住院风险增加存在关联,而mRNA疫苗未观察到关联。
  • ADEM和TM的绝对风险极低,分别为每百万剂0.78例和1.82例。
  • 任何潜在的ADEM或TM风险应与COVID-19疫苗已确立的保护获益及其并发症风险进行权衡。

研究设计与样本

  • 研究利用澳大利亚疫苗安全健康链接(VSHL)进行自身对照病例系列分析。
  • 比较COVID-19疫苗接种后42天风险窗与风险窗前后对照期的G040(ADEM)和G373(TM)ICD-10-AM编码住院相对发生率(RI)。

主要发现

  • ChAdOx1腺病毒载体COVID-19疫苗接种与ADEM所有剂次住院关联的RI为3.74(95%CI 1.02-13.70)。
  • ChAdOx1腺病毒载体COVID-19疫苗第1剂与TM住院关联的RI为2.49(95%CI 1.07-5.79)。
  • mRNA COVID-19疫苗与ADEM或TM未观察到关联。
  • 接种后ADEM绝对风险为每百万剂0.78例,TM绝对风险为每百万剂1.82例。

临床怎么用

  • 作者指出任何潜在的ADEM或TM风险应与COVID-19疫苗已确立的保护获益及其并发症风险进行权衡。
  • 本研究展示了GVDN合作利用大规模人群检查罕见疫苗安全问题的价值,以及链接人群水平数据集快速探索关联的价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute Disseminated Encephalomyelitis (ADEM) and Transverse Myelitis (TM) are within the group of immune mediated disorders of acquired demyelinating syndromes. Both have been described in temporal association following various vaccinations in case reports and case series and have been evaluated in observational studies. A recent analysis conducted by The Global Vaccine Data Network (GVDN) observed an excess of ADEM and TM cases following the adenoviral vectored ChAdOx1 nCoV-19 (AZD1222) and mRNA-1273 vaccines, compared with historically expected background rates from prior to the pandemic. Further epidemiologic studies were recommended to explore these potential associations. We utilized an Australian vaccine datalink, Vaccine Safety Health-Link (VSHL), to perform a self-controlled case series analysis for this purpose. VSHL was selected for this analysis as while VSHL data are utilised for GVDN association studies, they were not included in the GVDN observed expected analyses. The VSHL dataset contains vaccination records sourced from the Australian Immunisation Register, and hospital admission records from the Victorian Admitted Episodes Dataset for 6.7 million people. These datasets were used to determine the relative incidence (RI) of G040 (ADEM) and G373 (TM) ICD-10-AM coded admissions in the 42-day risk window following COVID-19 vaccinations as compared to control periods either side of the risk window. We observed associations between ChAdOx1 adenovirus vector COVID-19 vaccination and ADEM (all dose RI: 3.74 [95 %CI 1.02,13.70]) and TM (dose 1 RI: 2.49 [95 %CI: 1.07,5.79]) incident admissions. No associations were observed between mRNA COVID-19 vaccines and ADEM or TM. These findings translate to an extremely small absolute risk of ADEM (0.78 per million doses) and TM (1.82 per million doses) following vaccination; any potential risk of ADEM or TM should be weighed against the well-established protective benefits of vaccination against COVID-19 disease and its complications. This study demonstrates the value of the GVDN collaboration leveraging large population sizes to examine important vaccine safety questions regarding rare outcomes, as well as the value of linked population level datasets, such as VSHL, to rapidly explore associations that are identified.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Morgan HJ, Clothier HJ, Sepulveda Kattan G, et al. Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis. Vaccine. 2024. PMID: 38350771. doi:10.1016/j.vaccine.2024.01.099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。